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Summary. Enfuvirtide is the first approved membrane fusion inhibitor against HIV-1. Although 
this drug is effective against multi-drug resistant strains, the emergence of enfuvirtide-resistant 
strains has been reported in patients who have received an enfuvirtide-containing regimen. Based 
on the high affinity of synthetic HIV-1 gp41 C-terminal heptad repeat (C-HR) peptides to the 
counterpart trimeric N-terminal heptad repeat (N-HR) coiled-coil structure, a novel screening 
approach has been established to facilitate the identification of potent fusion inhibitors against wild-
type and enfuvirtide-resistant HIV-1. In this process, affinity selection using histidine-tagged N-HR 
peptides with the sequences derived from wild-type and resistant strains efficiently captured potent 
inhibitory peptides from a pool of highly water-soluble C-HR peptides with α-helix-inducible 
motifs. A highly potent peptide was found from a single amino acid substitution observed in an 





Several inhibitors that block viral attachment and the fusion process have been approved for the 
treatment of human immunodeficiency virus (HIV) in the past decade. The first fusion inhibitor, 
enfuvirtide (T-20), binds to the N-terminal heptad repeat (N-HR) of the HIV-1 envelop 
glycoprotein gp41,1 and prevents the formation of a fusogenic anti-parallel coiled-coil structure 
(known as the six-helical bundle) between N-HR and the C-terminal heptad repeat (C-HR) (Figure 
1a).2 Enfuvirtide is effective even against the clinical strains that are resistant to multiple drug 
classes such as reverse transcriptase inhibitors and protease inhibitors used in highly active 
antiretroviral therapy (HAART). However, the emergence of enfuvirtide-resistant strains has been 
reported in patients receiving long-term enfuvirtide treatment.3,4 
The primary evolution of enfuvirtide resistance occurs on gp41 N-HR, which attenuates the 
binding affinity with enfuvirtide, resulting in decreased drug susceptibility.3-5 The major primary 
mutations are V38A and N43D in the Leu33–Leu45 region of N-HR. These mutations subsequently 
lead to a secondary mutation appearing in C-HR, which can compensate the binding affinity 
between viral N-HR and C-HR for efficient gp41 folding.6 For example, N126K and S138A 
mutations have been reported to enhance the resistance induced by enfuvirtide and another 
inhibitory C-HR peptide, C34. These complementary mutations, which occur at the face-to-face 
positions of N-HR and C-HR verified by crystallographic studies,7–9 can restore the critical step 
required for viral infection into the target cells and eliminate the inhibitory effect of exogenous 
enfuvirtide. Recently, several novel fusion inhibitors such as tifuvirtide (T-1249)10 and sifuvirtide,11 
which are effective against these enfuvirtide-resistant viruses, have been reported. We have also 
demonstrated a novel tailored design of fusion inhibitors based on the enfuvirtide-resistant mutation 
to preempt this escape strategy of HIV-1.12 Enfuvirtide analogues carrying a substitution 
corresponding to the secondary mutation were found to exert potent anti-HIV activity against wild-
type and enfuvirtide-resistant strains with the primary mutations. Of interest, during this 
observation, we found that enfuvirtide analogues with other substitutions were also effective against 
these strains. Alternatively, modification of a single residue in C-HR such as Q141L, which is 
involved in the increased syncytium-forming ability of the mutant virus,13 led to an increase in the 
anti-HIV potency of inhibitor C34.14 These observations implied that the C-HR sequence with 
substitutions, which were not spontaneously elaborated by single nucleotide mutations from wild-
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type HIV-1, could represent potent fusion inhibitors. Encouraged by these results, the optimization 
of interactive residues of fusion inhibitors against wild-type and enfuvirtide-resistant viruses was 
undertaken.  
Affinity selection-mass spectrometry (AS-MS) is a promising methodology for compound 
screening, in which target molecule-bound components are captured from a pool of candidates and 
are identified by mass spectrometry. The successful applications of this technique are exemplified 
by the identification of kinase inhibitors15 and antifungal natural products.16 This simple selection 
process by virtue of the binding affinity can be a facile alternative to functional bioassays, although 
the functions and mechanisms of captured compounds for bioactivity cannot be determined. For 
medicinal chemistry of HIV fusion inhibitors, this approach should be suitable in the optimization 
of inhibitory C-HR peptides such as T-20EK17 and SC35EK.18 Taking advantage of the trimeric N-
HR coiled-coil as a target molecule, a mixture of C-HR peptides with a single amino acid 
substitution can be screened without using recombinant or clinical HIV strains.19,20 We envisioned 
that the competitive binding of C-HR components would capture relatively more potent anti-HIV 
peptides with higher affinity towards N-HR. Herein we report on the affinity-based screening 
technology and sequence–activity relationships for amino acid optimization in HIV-1 fusion 
inhibitors directed against enfuvirtide-resistant HIV strains. 
 
Results and Discussion 
T-20EK and SC35EK are characterized by repeated X-EE-XX-KK motifs that stabilize the 
bioactive α-helix structure of enfuvirtide and C34, respectively (Figure 1a). Potential electrostatic 
interactions between glutamic acid (Glu) and lysine (Lys) residues at i and i+4 positions, 
respectively, are distinct from the traditional stabilization with stapled covalent linkages.21,22 
Consistent substitution of the residues located on the non-interactive surface of the C-HR α-helix 
with Glu or Lys achieved an enhancement in affinity toward the N-HR sequence and anti-HIV 
activity. This process disclosed the indispensable residues in C-HR for direct interaction with viral 
N-HR (Figure 1b).23 Additionally, in contrast to native sequences of C-HR peptides that are highly 
hydrophobic, substitution with charged amino acids markedly improved the aqueous solubility of 
the peptides. This design allowed us to prepare a homogeneous mixture of the SC35EK derivatives 
and T-20EK derivatives at high concentrations.  
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Initially, C-HR peptide libraries with a variety of canonical amino acid substitutions at the 
positions to be optimized (Ser138 and Gln141) were prepared by a split-pool method. After the 
construction of the C-terminal sequence using a standard Fmoc-based solid-phase peptide synthesis 
approach, the resin was split into fractions at position 138 or 141, where proteinogenic amino acids 
except for cysteine were coupled in parallel. The 19 fractions were combined again and the N-
terminal sequence was constructed in one portion. All the protected peptide resins were treated with 
a cocktail of deprotection reagents, and the crude peptides were purified by reversed-phase HPLC 
to afford the expected peptides.  
Separately, in order to rationalize the selection process by affinity-based technology and to 
investigate the sequence-activity relationship, all C-HR peptides with a single substitution were 
prepared in parallel and were evaluated for the biological and physicochemical properties 
individually. The counterpart N-HR peptides of the wild-type and enfuvirtide-resistant variants 
(V38A and N43D) were also prepared. For affinity selection, the histidine tag (His6) sequence of 
the N-HR peptides was attached on the N-terminus via an aminocaproic acid-glycine dipeptide 
linker. This linker was incorporated to avoid the possible disruption of N-HR and C-HR interaction 
by positively charged His6-tag. Anti-HIV activities of all the C-HR peptides against laboratory 
wild-type HIV-1NL4-3 or the variants with enfuvirtide-resistant mutations were evaluated using the 
MAGI assay. Thermal stabilities of the potential six-helical bundles consisting of N-HR and C-HR 
peptides were evaluated by measuring the melting temperature (Tm) using the molar ellipticity value 
at 222 nm in circular dichroic (CD) spectra of N36/SC35EK or N54/T-20EK mixture (Figure S1). 
The AS-MS protocol was optimized using SC35EK derivatives (Table 1). A pool of 
SC35EKS138X was incubated with a wild-type N-HR peptide, N36 (10 µM) with an N-terminal His6-
tag, in HEPES buffer (pH 7.4). The potential six-helical bundles of N36–SC35EKS138X were 
captured by Ni-NTA agarose resin and were subsequently eluted with 50% AcOH (Figure 2a). The 
captured components were separated and characterized by LC-MS analysis, except that the peptides 
with Leu and Ile were observed as overlapping peaks of the same mass-to-charge ratio (Figure 2b). 
The recovery rate in affinity selection for relative binding ability to N36 was calculated from the 
detected signal of [M+3H]3+ and [M+4H]4+ ions of each C-HR peptide by the LC-MS analysis of 
captured peptides. Under the high concentration conditions (10 µM each of SC35EKS138X), several 
potent peptides including a resistant variant-derived S138A peptide were captured in high recovery 
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rates, while slightly less potent peptides such as SC35EKS138F and SC35EKS138Y were not detected. 
In contrast, when the total concentration of the mixture was nearly equal to the N36 concentration 
(0.6 µM each of SC35EKS138X), there was no discernible difference in the recovery rates of each 
peptide. The compound with the least potent anti-HIV activity in the series, SC35EKS138R, was 
recovered under this equimolar concentration conditions. This recovery suggested that the method 
is not effective under lower concentration conditions of C-HR peptides. A condition using 1 µM 
each of SC35EKS138X (total 19 µM of the mixture) for affinity selection was selected for further 
experiments, in which the recovery rate was found to positively correlate with the stability of the 
six-helical bundle (Figure 3a). Although an ideal linear correlation was not observed between the 
logarithmic EC50 of anti-HIV activity and the recovery rate (Figure 3b), the peptides, which were 
captured in relatively high yields by affinity selection, exhibited highly potent anti-HIV activity.  
The optimized condition was applied for the selection of T-20EKS138X derivatives (Table 2). The 
anti-HIV activity of T-20EKS138X was found to be dependent on the amino acid type at position 138. 
Substitution with aliphatic side-chain amino acids such as Ala, Ile, Leu, Met and Val, displayed 
highly potent anti-HIV activity, although significant stabilization of the N54–T-20EKS138X 
complexes was not observed. Gly- and Thr-substitutions were also observed to increase potency. In 
contrast, hydrophilic, charged and aromatic amino acid substitutions at position 138 reduced 
binding with N54. In our previous study, it was demonstrated that higher affinity with the N-HR 
sequence and more potent anti-HIV activity of C34S138A and T-20S138A were due to the dominant 
contribution of larger desolvation free energy of the hydrophobic side-chain.8 The structure–activity 
relationship of T-20EKS138X can be partially rationalized by the similar hydrophobic/hydrophilic 
properties of the side-chain. The recovery rates of T-20EKS138X in affinity selection showed good 
correlations with both anti-HIV activity and with thermal stability of the complexes (Figures 3c and 
3d). The peptides captured with more than 9% recovery yields exhibited sub-nanomolar potency 
along with Tm values >75°C. 
The anti-HIV activities of the series of peptides against recombinant viruses with either the 
enfuvirtide-resistant V38A or N43D mutation in N-HR were evaluated. The results of 
representative C-HR peptides, which were obtained by a single nucleotide mutation of HIV-1NL4-3, 
are shown in Table 3 and Figure S2. From Ser138 encoded by the TCG codon in wild-type NL4-3, 
Ala (GCG), Pro (CCG), Thr (ACG), Leu (TTG) and Trp (TGG) are possible mutations; the other 
 7 
mutations are silent (TCA, TCT, TCC) or a stop codon (TAG). The S138A substitution in both 
SC35EK and T-20EK enhanced the thermal stability of the N-HR/C-HR complex, indicating that 
this is a favorable mutation in terms of gp41 folding of the resistant virus.3,4 These peptides by 
mutant-directed design restored and enhanced the anti-HIV activity against enfuvirtide-resistant 
variants. The S138L peptide was also effective against both V38A and N43D strains; however, no 
emergence of a clinical variant having this mutation has been reported. Of interest, resistant viruses 
are unlikely to necessarily use the best C-HR substitution to complement the gp41 folding, 
presumably due to the low replication kinetics. These results indicate that the mutations observed in 
clinical variants can direct the position to be optimized for inhibitor design but not the most 
appropriate amino acids. In practice, several other substitutions by Ile and Met, which are irrelevant 
to single nucleotide mutations from the wild-type, also provided potent anti-HIV activity against the 
resistant strains (Table S4). In contrast, substitution with Pro or Trp for both peptides significantly 
decreased the activity, which is consistent with the results against the wild-type virus. Lower 
stabilities of the six-helical bundle structure consisting of S138T peptides and mutant N-HR 
peptides were shown, but SC35EKS138T was slightly more potent against both resistant viruses 
compared with the parent peptide.  
Using His-tagged N36 or N54 peptides with the V38A or N43D mutation, affinity selection 
experiments were performed for SC35EKS138X and T-20EKS138X including 19 components (Table 3 
and Table S4). Eight SC35EK derivatives captured in significantly high yields all showed potent 
anti-HIV activity against the V38A mutant. Moderate recovery yields of SC35EKS138E and 
SC35EKS138Y could result from potential false positive and negative results of the selection, 
respectively. Although T-20EK derivatives showed lower susceptibility against the V38A mutant in 
the MAGI assay, an association between the high recovery rate and more potent anti-HIV activity 
was observed such as S138A, S138I, S138L and S138M derivatives (Figures S3). Similar 
correlations were also obtained against N43D variants. SC35EKS138X and T-20EKS138X components, 
which exhibited subnanomolar potent bioactivity, were recovered in moderate to good yields. 
Overall favorable amino acids for position 138 of the wild-type were useful for designing C-HR 
peptides against V38A and N43D variants and vice versa, suggesting that the essential binding 
mode around this position is conserved even after acquiring the enfuvirtide resistance. 
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The structure-activity relationships of Q141 modifications were also investigated (Table 4). All 
SC35EKQ141X and T-20EKQ141X peptides except for the Q141P substitution exhibited similar anti-
HIV activity in the EC50 range of 1.6–3.2 nM and 0.51–4.6 nM, respectively. The significantly low 
Tm values of Q141P derivatives suggested that the sole proline residue precluded the formation of a 
bioactive α-helix structure. On the other hand, high potency of the other peptides independent of 
any other acyclic amino acid substitution at position 141 may be attributable to the lower 
importance of the Q141 position for the binding affinity between N-HR and C-HR than the S138 
position. Among these, Q141I, Q141L and Q141M peptides formed slightly more stable complexes 
with N36 or N54 and were captured at a relatively higher recovery rate by affinity selection. These 
substitutions were found to contribute to subnanomolar anti-HIV activity of T-20EK derivatives; 
however, these peptides were less valid for SC35EK derivatives.  
For both S138 and Q141 substitutions, it does not seem possible to distinguish between 
variations of a few nM in anti-HIV activity by affinity selection. This is particularly the case for the 
selections regarding less effective residues such as Q141 of SC35EK. In contrast, over a larger 
range of more than 2 orders of magnitude of affinity variations of T-20EK derivatives, the selection 
procedure correlated reasonably well with the anti-HIV activity and six-helix bundle stability. In 
both sequences, highly potent anti-HIV activity peptides were captured in good to high yields.  
 
Conclusions 
In conclusion, we have presented an affinity selection-mass spectrometry method to explore novel 
HIV-1 fusion inhibitors. Predicated on previous findings that the introduction of α-helix-inducible 
X-EE-XX-KK motifs into inhibitory C-HR peptides should improve peptide solubility in aqueous 
buffers and disclose the interactive surface to be optimized, a pool of SC35EK and T-20EK 
derivatives with a single modification at two interactive positions were screened using N-HR 
peptides corresponding to wild-type and enfuvirtide-resistant strains. Through the screening of 
position 138 on C-HR, it was demonstrated that potent anti-HIV peptides could be obtained by 
substitutions with resistance-related and resistance-independent amino acids. Since a wide variety 
of synthetic peptides with any unnatural amino acids or peptidomimetics could be employed as 
candidate components, the system should be applicable to screening for inhibitory α-helix peptides 
of coiled-coil interactions. The structure-activity relationships of C-HR peptides presented herein 
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may also be suitable in the design of the next-generation of fusion inhibitors. Additionally, since 
this process is considered to reproduce the evolutionary process of HIV-1 gp41 to select the 
appropriate folding partners in the presence of fusion inhibitors, the sequence-activity relationships 
could facilitate understanding of the underlying mechanisms of enfuvirtide resistance. 
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Figure 1. HIV-1 envelope protein gp41 and the amino acid sequences. (a) Schematic representation 
of HIV-1 gp41. FP: fusion peptide; TM: transmembrane domain; CP: cytoplasmic tail. (b) Helical-
wheel representation of C34/SC35EK and enfuvirtide/T-20EK.  
 
 
Figure 2. Affinity selection of the HIV-1 fusion inhibitors. (a) Protocol outlining the affinity 
selection of C-HR peptides using the histidine-tagged N-HR peptide. (b) HPLC profile of a pool of 
SC35EK derivatives with a single amino acid substitution at position 138 [Cosmosil 5C18 AR-II 
column; linear 30–40% MeCN gradient over 40 min; flow rate, 1 cm3 min-1; detection at 220 nm].  
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Figure 3. Correlation between the recovery rate and the thermal stability, or the anti-HIV activity. 
(a, b) SC35EKS138X; (c, d) T-20EKS138X. R2 values for the correlation of SC35EKS138X data were 
calculated without using the data points of S138R/K/P/D mutants (n = 15). 
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Table 1. Optimization of the affinity selection protocol.  
Recovery (%)a 
Concentration of SC35EKS138X (µM) X 





Ser 22.8 19.2 11.5 5.8 1.0 ± 0.14 81.6 
Ala 30.7 22.5 11.5 5.3 1.2 ± 0.12 86.4 
Asp 0.7 0.0 0.0 4.3 15 ± 3.3 59.7 
Glu 1.3 1.0 1.8 5.1 15 ± 0.69 66.2 
Phe 0.7 0.6 4.0 6.3 1.5 ± 0.10 72.9 
Gly 13.8 14.4 11.6 5.9 1.9 ± 0.26 79.1 
His 0.9 0.6 2.4 5.7 1.9 ± 0.57 62.9 
Ile 4.7d 7.6d 11.3d 6.9d 1.3 ± 0.54  84.6 
Lys 0.2 0.1 0.0 3.6 8.2 ± 1.7 53.5 
Leu 4.7d 7.6d 11.3d 6.9d 0.93 ± 0.16 83.2 
Met 8.9 13.3 12.5 6.8 0.68 ± 0.06 84.1 
Asn 1.1 0.5 4.3 6.4 2.2 ± 0.47 69.0 
Pro 0.4 0.2 0.1 4.5 35 ± 9.2 56.1 
Gln 0.9 0.5 2.1 6.1 2.4 ± 0.79 65.9 
Arg 0.3 0.1 0.0 2.5 280 ± 47 52.3 
Thr 9.0 12.8 11.7 5.7 1.8 ± 0.27 79.7 
Val 2.8 6.0 12.1 7.0 1.9 ± 0.64 79.9 
Trp 0.5 0.3 0.9 6.2 3.1 ± 0.52 66.4 
Tyr 0.5 0.4 2.3 5.9 1.9 ± 0.71 68.0 
aThe recovery rate was determined from the relative detected signals of [M+3H]3+ and [M+4H]4+ 
ions by LC–MS analysis. bEC50 was determined as the concentration that blocked HIV-1NL4-3 
replication by 50% in the MAGI assay. To improve the replication kinetics, the D36G mutation, 
observed in the majority of HIV-1 strains, was introduced into the NL4-3 background used in this 
study. cTm values were defined by the midpoint of the thermal unfolding transition state measured 
by monitoring the molar ellipticity at 222 nm of N36/SC35EKS138X mixture. dCombined yield of 
138I and 138L derivatives.  
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Table 2. Recovery rate in affinity selection and anti-HIV activity of T-20EKS138X, and the thermal 
stability of the N54–T-20EKS138X complex. 












Ser 10.0 1.1 ± 0.2 78.8      
Ala 10.0 0.3 ± 0.1 80.1  Met 9.9 0.2 ± 0.1 79.0 
Asp 1.5 330 ± 96 56.5  Asn 3.5 4.8 ± 1.6 65.7 
Glu 2.2 230 ± 31 61.0  Pro 0.2 44 ± 8 55.5 
Phe 5.8 2.8 ± 0.2 64.6  Gln 2.2 7.9 ± 3.4 60.0 
Gly 9.6 0.4 ± 0.2 76.7  Arg 1.5 320 ± 88 49.4 
His 3.2 35 ± 10 58.5  Thr 10.0 0.4 ± 0.2 75.9 
Ile 10.4d 0.4 ± 0.1 79.7  Val 9.4 0.3 ± 0.1 76.0 
Lys 0.8 330 ± 67 50.6  Trp 5.2 20 ± 9 62.0 
Leu 10.4d 0.4 ± 0.3 77.6  Tyr 4.7 5.0 ± 1.5 61.1 
aThe recovery rate was determined from the relative detected signals of [M+3H]3+ and [M+4H]4+ 
ions by LC–MS analysis. bEC50 was determined as the concentration that blocked HIV-1NL4-3 
replication by 50% in the MAGI assay. To improve the replication kinetics, the D36G mutation, 
observed in the majority of HIV-1 strains, was introduced into the NL4-3 background used in this 
study. cTm values were defined by the midpoint of the thermal unfolding transition state measured 
by monitoring the molar ellipticity at 222 nm of N54/T-20EKS138X mixture. dCombined yield of 
138I and 138L derivatives. 
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Table 3. Peptide recovery in affinity selection, anti-HIV activity and thermal stability of the six-
helix bundles of C-HR peptides against enfuvirtide-resistant variants.  
SC35EKS138X  T-20EKS138X 












HIVV38A       
Ser 11.8 1.1 ± 0.3 72.6  9.3 3.4 ± 1.4 60.0 
Ala 11.4 0.7 ± 0.2 76.1  10.0 2.2 ± 0.8 64.6 
Leu 10.3d 0.8 ± 0.1 75.0  10.1d 3.4 ± 1.6 57.5 
Pro 0.4 340 ± 61 56.3  0.0 >1000 49.7 
Thr 10.8 0.8 ± 0.1 70.4  8.1 28 ± 12 57.8 
Trp 1.0 22 ± 5.6 64.6  7.7 >1000 53.2 
HIVN43D       
Ser 10.9 0.3 ± 0.1 69.9  7.4 2.0 ± 0.4 65.3 
Ala 12.9 0.2 ± 0.1 74.4  10.2 0.3 ± 0.1 71.9 
Leu 12.9d 0.2 ± 0.1 80.0  10.8d 0.2 ± 0.1 74.0 
Pro 0.3 130 ± 52 55.6  0.3 430 ± 160 55.0 
Thr 9.4 0.3 ± 0.1 67.5  6.1 3.7 ± 0.1 62.4 
Trp 2.4 2.7 ± 0.6 66.0  7.6 220 ±17 61.4 
aThe recovery rate was determined from the relative detected signals of [M+3H]3+ and [M+4H]4+ 
ions by LC–MS analysis. bEC50 was determined as the concentration that blocked HIV-1NL4-3 
replication by 50% in the MAGI assay. To improve the replication kinetics, the D36G mutation, 
observed in the majority of HIV-1 strains, was introduced into the NL4-3 background used in this 
study. cTm values were defined by the midpoint of the thermal unfolding transition state measured 
by monitoring the molar ellipticity at 222 nm of N36V38A/SC35EKS138X, N36N43D/SC35EKS138X, 
N54V38A/T-20EKS138X or N54N43D/T-20EKS138X mixture. dCombined yield of 138I and 138L 
derivatives.  
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Table 4. Peptide recovery in affinity selection, anti-HIV activity and thermal stability of the six-














Gln 10.1 2.6 ± 0.3 81.6 8.2e 1.5 ± 0.6 78.8 
Ala 6.6 1.6 ± 0.6 76.1 5.6 2.7 ± 0.3 70.4 
Asp 4.5 2.9 ± 0.1 75.1 8.2 3.5 ± 0.7 71.4 
Glu 4.3 2.4 ± 0.4 76.2 8.2e 3.8 ± 0.8 71.8 
Phe 5.7 2.6 ± 0.4 76.7 5.3 2.6 ± 0.9 64.0 
Gly 3.8 2.3 ± 0.7 71.0 3.4 3.0 ± 0.6 66.2 
His 4.3 2.0 ± 0.5 72.6 3.7 3.0 ± 0.6 68.4 
Ile 8.2d 2.9 ± 0.4 79.7 10.4d 0.8 ± 0.3 74.0 
Lys 4.8 2.7 ± 0.5 69.2 4.8 3.8 ± 0.3 65.3 
Leu 8.2d 2.7 ± 0.9 83.8 10.4d 0.5 ± 0.2 77.4 
Met 6.0 2.0 ± 0.3 80.2 9.2 0.9 ± 0.1 74.6 
Asn 4.0 2.5 ± 0.5 73.4 4.4 3.6 ± 0.7 69.0 
Pro 0.0 58 ± 16 60.2 0.3 >1000 52.0 
Arg 7.6 2.5 ± 0.1 71.5 7.2 1.5 ± 0.3 68.9 
Ser 4.0 2.5 ± 0.7 72.4 3.2 4.6 ± 1.4 66.7 
Thr 7.3 3.2 ± 0.6 76.7 6.9 2.1 ± 0.5 71.6 
Val 6.2 2.2 ± 0.6 77.7 6.1 2.9 ± 0.2 70.5 
Trp 7.1 1.7 ± 0.2 77.1 8.1 2.5 ± 0.1 68.8 
Tyr 5.5 2.2 ± 0.6 76.3 4.9 2.3 ± 0.9 67.7 
aThe recovery rate was determined from the relative detected signals of [M+3H]3+ and [M+4H]4+ 
ions by LC–MS analysis. bEC50 was determined as the concentration that blocked HIV-1NL4-3 
replication by 50% in the MAGI assay. To improve the replication kinetics, the D36G mutation, 
observed in the majority of HIV-1 strains, was introduced into the NL4-3 background used in this 
study. cTm values were defined by the midpoint of the thermal unfolding transition state measured 
by monitoring the molar ellipticity at 222 nm of N36/SC35EKQ141 or N54/T-20EKQ141 mixture. dCombined yield of 141I and 141L derivatives. eCombined yield of 141E and 141Q derivatives. 
 
